Quantum-SI (NASDAQ: QSI) is a life sciences company on a mission to revolutionize proteomics, the large-scale study of proteins. The company developed Platinum™, the first next-generation single-molecule protein sequencing platform. This technology aims to empower researchers and clinicians by enabling routine, comprehensive, and unbiased analysis of the proteome. By providing deeper insights into protein structure, function, and modifications, Quantum-SI's platform has the potential to significantly accelerate drug discovery, advance diagnostics, and broaden our understanding of biology and disease. Their approach utilizes semiconductor chip technology for real-time, single-molecule protein analysis.
Serves as the global headquarters, encompassing primary research and development labs, corporate offices, and key operations for the manufacturing and assembly of their Platinum™ protein sequencing instruments and proprietary consumables (chips).
State-of-the-art laboratories for proteomics research, specialized cleanroom environments for semiconductor chip manufacturing (core to their sequencing technology), and advanced instrument development facilities. The space is designed to support interdisciplinary scientific collaboration.
Quantum-SI fosters an innovative, collaborative, and mission-driven work culture. As a company at the forefront of a new technological field, the environment is likely fast-paced, emphasizing scientific excellence, problem-solving, and a shared goal of transforming proteomics.
The Branford headquarters is central to Quantum-SI's strategy, housing the core innovation, product development, and leadership functions. Its location within Connecticut's life science corridor provides access to specialized talent, research collaborations, and a supportive biotech ecosystem, crucial for its pioneering work in protein sequencing.
While Quantum-SI's primary physical operations (R&D, manufacturing, corporate) are based in the United States (Connecticut and California), the company aims for a global impact with its protein sequencing technology. They support a worldwide customer base of academic institutions, pharmaceutical companies, and biotech organizations through direct sales, and are building out distribution networks and collaborations to make their Platinum™ platform accessible to researchers globally. Their commercialization strategy includes targeting key research markets in North America, Europe, and Asia-Pacific.
29 Business Park Drive
Branford
CT
USA
Address: Leased office and laboratory space; specific street address not publicly detailed by the company.
To tap into the rich talent pool and collaborative opportunities within the Southern California biotech ecosystem, complementing the R&D efforts at the Connecticut headquarters and potentially supporting West Coast commercial activities.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Quantum-Si' leadership includes:
Quantum-Si has been backed by several prominent investors over the years, including:
Over the past 12 months (approx. May 2023 - May 2024), Quantum-SI has made significant updates to its executive team, notably appointing a new Chief Financial Officer and a new Chief Commercial Officer to strengthen its financial operations and drive commercial growth.
Discover the tools Quantum-Si uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Quantum-SI likely uses a standard corporate email format. Based on industry conventions and patterns observed for similar companies, the most common format is expected to be the first initial followed by the last name.
[first_initial][last]@quantum-si.com
Format
jhawkins@quantum-si.com
Example
80%
Success rate
GlobeNewswire • March 5, 2024
Quantum-SI announced the appointment of Grace Johnston, Ph.D., as its Chief Commercial Officer, effective March 4, 2024. Dr. Johnston will lead global commercial strategies, sales, and marketing efforts for Quantum-SI's Platinum™ protein sequencing platform....more
GlobeNewswire • February 27, 2024
Quantum-SI reported its financial results for Q4 and FY 2023, highlighting progress in the commercialization of its Platinum™ platform, instrument placements, and ongoing R&D efforts. The company also provided updates on its operational strategy and outlook for 2024....more
GlobeNewswire • November 2, 2023
Quantum-SI announced the appointment of Jeff Keyes as its Chief Financial Officer, effective November 6, 2023. Mr. Keyes brings extensive financial leadership experience in the life sciences and technology sectors to support Quantum-SI's growth....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Quantum-Si, are just a search away.